Renata Valuation

Is RENATA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RENATA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RENATA (BDT742.6) is trading above our estimate of fair value (BDT467.25)

Significantly Below Fair Value: RENATA is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for RENATA?

Other financial metrics that can be useful for relative valuation.

RENATA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.8x
Enterprise Value/EBITDA23x
PEG Ratio1.3x

Price to Earnings Ratio vs Peers

How does RENATA's PE Ratio compare to its peers?

The above table shows the PE ratio for RENATA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average31.7x
BXPHARMA Beximco Pharmaceuticals
9.7x15.6%৳51.5b
SQURPHARMA Square Pharmaceuticals
9.4x12.2%৳190.3b
BEACONPHAR Beacon Pharmaceuticals
71.4xn/a৳33.3b
ORIONPHARM Orion Pharma
36.4xn/a৳16.6b
RENATA Renata
37.1x29.0%৳85.2b

Price-To-Earnings vs Peers: RENATA is expensive based on its Price-To-Earnings Ratio (37.1x) compared to the peer average (31.7x).


Price to Earnings Ratio vs Industry

How does RENATA's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.7%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.7%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: RENATA is expensive based on its Price-To-Earnings Ratio (37.1x) compared to the Asian Pharmaceuticals industry average (25.3x).


Price to Earnings Ratio vs Fair Ratio

What is RENATA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RENATA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio37.1x
Fair PE Ratio18.3x

Price-To-Earnings vs Fair Ratio: RENATA is expensive based on its Price-To-Earnings Ratio (37.1x) compared to the estimated Fair Price-To-Earnings Ratio (18.3x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.